Nature Medicine

Papers
(The median citation count of Nature Medicine is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
The proximal origin of SARS-CoV-23468
Temporal dynamics in viral shedding and transmissibility of COVID-193070
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection2992
Post-acute COVID-19 syndrome2862
Antibody responses to SARS-CoV-2 in patients with COVID-192292
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections2165
Extrapulmonary manifestations of COVID-192129
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes2035
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-191954
A global survey of potential acceptance of a COVID-19 vaccine1765
An inflammatory cytokine signature predicts COVID-19 severity and survival1741
Respiratory virus shedding in exhaled breath and efficacy of face masks1585
Attributes and predictors of long COVID1526
A serological assay to detect SARS-CoV-2 seroconversion in humans1502
Age-dependent effects in the transmission and control of COVID-19 epidemics1258
Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy1194
A single-cell atlas of the peripheral immune response in patients with severe COVID-191191
Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding1123
Real-time tracking of self-reported symptoms to predict potential COVID-191090
Long-term cardiovascular outcomes of COVID-19984
Digital technology and COVID-19921
Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China885
Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19827
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma815
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection795
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies758
A dynamic COVID-19 immune signature includes associations with poor prognosis704
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers702
Artificial intelligence–enabled rapid diagnosis of patients with COVID-19668
Digital technologies in the public-health response to COVID-19658
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries642
Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia612
AI in health and medicine597
Seasonal coronavirus protective immunity is short-lasting582
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies578
Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation518
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies517
Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries495
SARS-CoV-2 infection of the oral cavity and saliva494
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera482
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2477
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma472
Immune determinants of COVID-19 disease presentation and severity467
Determinants of COVID-19 disease severity in patients with cancer464
Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong463
Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration454
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals453
Joint international consensus statement for ending stigma of obesity440
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial439
Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda434
Looking beyond COVID-19 vaccine phase 3 trials433
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination430
Single-cell multi-omics analysis of the immune response in COVID-19427
Long COVID in a prospective cohort of home-isolated patients426
Long COVID after breakthrough SARS-CoV-2 infection426
Targeting metastatic cancer423
Infection of bat and human intestinal organoids by SARS-CoV-2415
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein411
Understanding COVID-19 vaccine hesitancy411
Human postprandial responses to food and potential for precision nutrition403
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study402
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa399
Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus396
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine387
Symptoms and risk factors for long COVID in non-hospitalized adults379
Biomarkers for neurodegenerative diseases379
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK374
If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future363
Intratumoral heterogeneity in cancer progression and response to immunotherapy362
A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors360
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection358
Human–computer collaboration for skin cancer recognition357
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer350
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes350
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19348
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy345
Deep learning in histopathology: the path to the clinic342
On the responsible use of digital data to tackle the COVID-19 pandemic342
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants341
A deep learning system for differential diagnosis of skin diseases340
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease340
Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension335
Four distinct trajectories of tau deposition identified in Alzheimer’s disease335
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study335
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination334
Disease and healthcare burden of COVID-19 in the United States334
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial329
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial325
Partial recovery of visual function in a blind patient after optogenetic therapy325
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis324
Brown adipose tissue is associated with cardiometabolic health321
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial321
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China318
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer318
Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids317
Modeling COVID-19 scenarios for the United States315
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar315
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas314
Sixteen novel lineages of SARS-CoV-2 in South Africa313
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer313
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant312
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar310
Toward personalized treatment approaches for non-small-cell lung cancer310
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination301
Wearable sensor data and self-reported symptoms for COVID-19 detection301
Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection300
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis294
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination290
SARS-CoV-2 variants of concern are emerging in India290
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant289
Federated learning for predicting clinical outcomes in patients with COVID-19288
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial288
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors282
Single-cell transcriptomic atlas of the human endometrium during the menstrual cycle280
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial279
Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries274
Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells274
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial273
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England271
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial268
Skin-interfaced biosensors for advanced wireless physiological monitoring in neonatal and pediatric intensive-care units268
Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers264
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination263
Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling263
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters261
Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States261
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence261
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals255
A single-cell landscape of high-grade serous ovarian cancer255
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial255
Combating COVID-19: health equity matters254
Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist251
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease248
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults245
Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics244
Targeting the HIF2–VEGF axis in renal cell carcinoma241
Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands239
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection237
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension237
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial237
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade235
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses234
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom234
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma234
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus233
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection233
Cellular senescence and senolytics: the path to the clinic232
A stochastic agent-based model of the SARS-CoV-2 epidemic in France231
Acute and postacute sequelae associated with SARS-CoV-2 reinfection231
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin229
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies226
Caring for patients with cancer in the COVID-19 era226
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster225
Microglial activation and tau propagate jointly across Braak stages222
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy220
Unexplained post-acute infection syndromes220
How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals219
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures218
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer208
Long-term neurologic outcomes of COVID-19208
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern207
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps205
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies204
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade203
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring202
A guide to immunotherapy for COVID-19201
Vaccine development for emerging infectious diseases200
Closed-loop neuromodulation in an individual with treatment-resistant depression200
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial199
Early prediction of circulatory failure in the intensive care unit using machine learning198
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19198
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)198
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland198
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial195
The distribution of cellular turnover in the human body195
Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma195
Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes195
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California194
Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populations192
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial191
IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies190
Therapeutic base editing of human hematopoietic stem cells188
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2185
Articular cartilage regeneration by activated skeletal stem cells185
Crowding and the shape of COVID-19 epidemics184
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models184
A roadmap to increase diversity in genomic studies184
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma184
A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity183
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results182
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study182
Multimodal biomedical AI182
Large language models in medicine181
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma181
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer180
Using a real-world network to model localized COVID-19 control strategies180
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma179
Modeling shield immunity to reduce COVID-19 epidemic spread178
Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach177
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial176
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2174
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma174
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial173
The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk173
The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology172
COVID-19 dynamics after a national immunization program in Israel171
Delayed production of neutralizing antibodies correlates with fatal COVID-19170
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease170
Global maps of travel time to healthcare facilities168
Modeling transmission of SARS-CoV-2 Omicron in China168
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors168
Predicting conversion to wet age-related macular degeneration using deep learning166
Increased global integration in the brain after psilocybin therapy for depression165
A correlate of protection for SARS-CoV-2 vaccines is urgently needed165
Reconstruction of the human blood–brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericytes165
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial164
SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland164
Reporting guidelines for human microbiome research: the STORMS checklist162
Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis162
Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes160
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors159
Developing specific reporting guidelines for diagnostic accuracy studies assessing AI interventions: The STARD-AI Steering Group158
COVID-19 in Africa: the spread and response157
Prediction of mortality from 12-lead electrocardiogram voltage data using a deep neural network157
Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes155
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1154
Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy153
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial153
Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson’s disease152
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers152
Wearable-device-measured physical activity and future health risk152
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis152
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer150
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial150
Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium150
Misinformation: susceptibility, spread, and interventions to immunize the public149
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma149
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial149
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis146
COVID-19 and resilience of healthcare systems in ten countries146
Targeting the gut and tumor microbiota in cancer145
The landscape of mRNA nanomedicine144
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021144
A neuroimaging biomarker for striatal dysfunction in schizophrenia144
Colibactin DNA-damage signature indicates mutational impact in colorectal cancer143
An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy142
Artificial intelligence–enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial142
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial141
An algorithmic approach to reducing unexplained pain disparities in underserved populations140
Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice139
0.093830823898315